Yanling WangSr. Director of Synthetic Biology, Protein Expression at HenliusSpeaker
Profile
I have been working for 11 years focusing on stable cell line development for manufacture and protein expression for early stage lead discovery and function validation. We have established the expression system from random integration to site specific integration, from UCOE to GS, then GS-transposon system. The project involved monoclonal antibody, VHH nanobody, bi-specific, and asymmetrical Abs. Also include the biosimilar and innovated molecules.
Agenda Sessions
Address the CMC Development Challenges of Bispecifics, Including Immunocytokines Combining Antibodies with Cytokines, and Fusion Proteins Combining Antibodies with Enzymes
, 9:00amView SessionBeyond mAbs: The Next Wave of Therapeutic Innovation for a New Era
, 3:00pmView Session